232 related articles for article (PubMed ID: 28576443)
21. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study.
Muchtar E; Gatt ME; Rouvio O; Ganzel C; Chubar E; Suriu C; Tadmor T; Shevetz O; Lavi N; Shochat T; Cohen YC; Avivi I; Raanani P; Magen H
Br J Haematol; 2016 Jan; 172(1):89-96. PubMed ID: 26567759
[TBL] [Abstract][Full Text] [Related]
22. Carfilzomib: a second-generation proteasome inhibitor for the treatment of relapsed and refractory multiple myeloma.
Thompson JL
Ann Pharmacother; 2013 Jan; 47(1):56-62. PubMed ID: 23300152
[TBL] [Abstract][Full Text] [Related]
23. A practical review on carfilzomib in multiple myeloma.
Muchtar E; Gertz MA; Magen H
Eur J Haematol; 2016 Jun; 96(6):564-77. PubMed ID: 26893241
[TBL] [Abstract][Full Text] [Related]
24. Optimizing Immunomodulatory Drug With Proteasome Inhibitor Combinations in Newly Diagnosed Multiple Myeloma.
Ntanasis-Stathopoulos I; Terpos E; Dimopoulos MA
Cancer J; 2019; 25(1):2-10. PubMed ID: 30694854
[TBL] [Abstract][Full Text] [Related]
25. An open-label phase I/II study of cyclophosphamide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed myeloma.
Nishihori T; Baz R; Shain K; Kim J; Ochoa-Bayona JL; Yue B; Sullivan D; Dalton W; Alsina M
Eur J Haematol; 2015 Nov; 95(5):426-35. PubMed ID: 25600676
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
27. U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma.
Herndon TM; Deisseroth A; Kaminskas E; Kane RC; Koti KM; Rothmann MD; Habtemariam B; Bullock J; Bray JD; Hawes J; Palmby TR; Jee J; Adams W; Mahayni H; Brown J; Dorantes A; Sridhara R; Farrell AT; Pazdur R
Clin Cancer Res; 2013 Sep; 19(17):4559-63. PubMed ID: 23775332
[TBL] [Abstract][Full Text] [Related]
28. Relationship Between Carfilzomib Dose and Efficacy Outcomes in Patients With Relapsed and/or Refractory Multiple Myeloma.
Squifflet P; Michiels S; Siegel D; Vij R; Jagannath S; Saad ED; Rajangam K; Ro SK; Buyse M
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):680-6. PubMed ID: 26482107
[TBL] [Abstract][Full Text] [Related]
29. Thrombotic microangiopathy in untreated myeloma patients receiving carfilzomib, cyclophosphamide and dexamethasone on the CARDAMON study.
Camilleri M; Cuadrado M; Phillips E; Wilson W; Jenner R; Pang G; Kamora S; Streetly M; Popat R; Bygrave C; Owen R; Cavenagh J; Chapman M; Sive J; Eccersley L; Sheaff M; Benjamin R; Ramasamy K; Cook G; Virchis A; Chavda SJ; Clifton-Hadley L; Scully MA; Yong K
Br J Haematol; 2021 May; 193(4):750-760. PubMed ID: 33650100
[TBL] [Abstract][Full Text] [Related]
30. Carfilzomib: a novel agent for multiple myeloma.
Redic K
J Pharm Pharmacol; 2013 Aug; 65(8):1095-106. PubMed ID: 23837578
[TBL] [Abstract][Full Text] [Related]
31. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
32. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma.
Stewart AK; Rajkumar SV; Dimopoulos MA; Masszi T; Špička I; Oriol A; Hájek R; Rosiñol L; Siegel DS; Mihaylov GG; Goranova-Marinova V; Rajnics P; Suvorov A; Niesvizky R; Jakubowiak AJ; San-Miguel JF; Ludwig H; Wang M; Maisnar V; Minarik J; Bensinger WI; Mateos MV; Ben-Yehuda D; Kukreti V; Zojwalla N; Tonda ME; Yang X; Xing B; Moreau P; Palumbo A;
N Engl J Med; 2015 Jan; 372(2):142-52. PubMed ID: 25482145
[TBL] [Abstract][Full Text] [Related]
33. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial.
Younes A; Berdeja JG; Patel MR; Flinn I; Gerecitano JF; Neelapu SS; Kelly KR; Copeland AR; Akins A; Clancy MS; Gong L; Wang J; Ma A; Viner JL; Oki Y
Lancet Oncol; 2016 May; 17(5):622-31. PubMed ID: 27049457
[TBL] [Abstract][Full Text] [Related]
34. Enzymatic activities of circulating plasma proteasomes in newly diagnosed multiple myeloma patients treated with carfilzomib, lenalidomide and dexamethasone.
Manasanch EE; de Larrea CF; Zingone A; Steinberg SM; Kwok M; Tageja N; Bhutani M; Kazandjian D; Roschewski M; Wu P; Carter G; Zuchlinski D; Mulquin M; Lamping L; Costello R; Burton D; Gil LA; Figg WD; Maric I; Calvo KR; Yuan C; Stetler-Stevenson M; Korde N; Landgren O
Leuk Lymphoma; 2017 Mar; 58(3):639-645. PubMed ID: 27687480
[TBL] [Abstract][Full Text] [Related]
35. 'Real-life' experience of preapproval carfilzomib-based therapy in myeloma - analysis of cardiac toxicity and predisposing factors.
Danhof S; Schreder M; Rasche L; Strifler S; Einsele H; Knop S
Eur J Haematol; 2016 Jul; 97(1):25-32. PubMed ID: 26331915
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of syncopated thalidomide, lenalidomide, and weekly dexamethasone in patients with newly diagnosed multiple myeloma.
Tufail M; Siegel DS; McBride L; Bilotti E; Bello E; Anand P; Olivo K; Bendarz U; McNeill A; Vesole DH
Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):186-90. PubMed ID: 22381702
[TBL] [Abstract][Full Text] [Related]
37. A phase I/II study of carfilzomib 2-10-min infusion in patients with advanced solid tumors.
Papadopoulos KP; Burris HA; Gordon M; Lee P; Sausville EA; Rosen PJ; Patnaik A; Cutler RE; Wang Z; Lee S; Jones SF; Infante JR
Cancer Chemother Pharmacol; 2013 Oct; 72(4):861-8. PubMed ID: 23975329
[TBL] [Abstract][Full Text] [Related]
38. Carfilzomib-containing combinations as frontline therapy for multiple myeloma: A meta-analysis of 13 trials.
Sheng Z; Li G; Li B; Liu Y; Wang L
Eur J Haematol; 2017 Jun; 98(6):601-607. PubMed ID: 28295593
[TBL] [Abstract][Full Text] [Related]
39. A phase 1b dose-escalation study of carfilzomib in combination with thalidomide and dexamethasone in patients with relapsed/refractory systemic immunoglobulin light chain amyloidosis.
Ravichandran S; Hall A; Jenner M; Garg M; Kishore B; Lachmann H; Gillmore J; Pitchford A; Oughton JB; Mahmood S; Sachchithantham S; Hawkins P; Brown S; Wechalekar A
Amyloid; 2023 Sep; 30(3):290-296. PubMed ID: 37216268
[TBL] [Abstract][Full Text] [Related]
40. Carfilzomib or bortezomib in combination with cyclophosphamide and dexamethasone followed by carfilzomib maintenance for patients with multiple myeloma after one prior therapy: results from a multicenter, phase II, randomized, controlled trial (MUK
Yong KL; Hinsley S; Auner HW; Bygrave C; Kaiser MF; Ramasamy K; De Tute RM; Sherratt D; Flanagan L; Garg M; Hawkins S; Williams C; Cavenagh J; Rabin NK; Croft J; Morgan G; Davies F; Owen RG; Brown SR
Haematologica; 2021 Oct; 106(10):2694-2706. PubMed ID: 33910333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
